Pfizer’s Strategic Focus and Market Challenges Justify Hold Rating Amid Uncertainties

Analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer (PFE – Research Report), retaining the price target of $25.00.

Geoff Meacham has given his Hold rating due to a combination of factors influencing Pfizer’s current market position. One of the primary considerations is the company’s strategic focus on maintaining dividends and operational efficiency, which is supported by strong first-quarter results. However, the ongoing complexities in the supply chain and the uncertainties surrounding the Most Favored Nation (MFN) pricing policy contribute to a cautious outlook.
Additionally, while Pfizer is actively pursuing opportunities in the biotech sector, particularly in oncology and cardio-metabolic assets, the market is currently overvalued, necessitating a disciplined approach to business development. The looming loss of exclusivity on key drugs between 2026 and 2029 also adds a layer of uncertainty to the company’s future revenue streams. These factors collectively justify a Hold rating, as they present both opportunities and challenges that Pfizer needs to navigate carefully.

In another report released yesterday, Bernstein also reiterated a Hold rating on the stock with a $30.00 price target.

PFE’s price has also changed slightly for the past six months – from $24.940 to $23.520, which is a -5.69% drop .